key: cord-0771417-tx6q4p24
authors: Zequn, Zheng; Yujia, W.U.; Dingding, Q.I.A.N.; Jiangfang, L.I.A.N.
title: Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
date: 2020-12-18
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2020.173813
sha: 0f43c69ce875aa75146225310a325a40d9b068f9
doc_id: 771417
cord_uid: tx6q4p24

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an enormous challenge to the medical system, especially the lack of safe and effective COVID-19 treatment methods, forcing people to look for drugs that may have therapeutic effects as soon as possible. Some old drugs have shown clinical benefits after a few small clinical trials that attracted great attention. Clinically, however, many drugs, including those currently used in COVID-19, such as chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir, may cause cardiotoxicity by acting on cardiac potassium channels and the hERG channel through their off-target effects. The blocking of the hERG channel prolongs QT intervals on electrocardiograms; thus, it might induce severe ventricular arrhythmias and even sudden cardiac death. Therefore, while focusing on the efficacy of COVID-19 drugs, the fact that they block hERG channels to cause arrhythmias cannot be ignored. To develop safer and more effective drugs, it is necessary to understand the interactions between drugs and the hERG channel and the molecular mechanism behind this high affinity. In this review, we focus on the biochemical and molecular mechanistic aspects of drug-related blockade of the hERG channel to provide insights into QT prolongation caused by off-label use of related drugs in COVID-19, and hope to weigh the risks and benefits when using these drugs.

encodes the pore-forming alpha subunit of a fast component of the delayed rectifier potassium channel (I Kr ), which plays a fundamental role in the three-phase repolarization of the ventricular action potential, i.e., the repolarization of cardiac myocytes (Vandenberg et al., 2012) . hERG channel dysfunction contributes to a partial or complete reduction in the I Kr current, resulting in prolonged action potential duration (APD) (Smith et al., 2016) , manifested as a prolonged QT interval on an ECG (Fig 1B) , and if the extension exceeds the normal range (440 ms in men, 460 ms in women), LQTS results (Schwartz and Ackerman, 2013; van Noord et al., 2010) . Clinically, LQTS caused by hERG deficiency is called type 2 LQTS (LQT2), which is the second most common subtype of LQTS (Kapplinger et al., 2009) .

The electrical activity of the heart is mediated by the regulation of the channels in which ions flow into and out of cardiomyocytes. Theoretically, ion currents that constitute the ventricular action potential include inward and outward currents, and the balance of outward and inward currents is the key to the formation of normal APD. Na + and L-type Ca 2+ currents (I Na and I CaL , respectively) are the most important inward currents in cardiomyocytes, and the K + current (I K ) is the major outward current. Increased inward current or a weakening of outward currents due to drug effects can result in a prolongation of APD, leading to a prolonged QT interval ( Fig 1A) (van Noord et al., 2010) . Excessive prolongation can facilitate the production of early after depolarization (EAD) in three-phase repolarization that will trigger TdP and even ventricular fibrillation if EAD reaches its threshold (Albert and Schuller, 2014) .

A decrease in outward potassium currents causes a longer repolarization time due to the blocking of the hERG channel, the effect of which is consistent with strengthening sodium or calcium currents. Therefore, the effect of drug inhibition on the hERG channel appears to be corrected by drugs that block I Na and I CaL . A classic example is amiodarone, a widely used class III antiarrhythmic drug that inhibits multiple ion channels to balance the blocking of I Kr ; therefore, amiodarone leads to rare malignant arrhythmic events generated by potassium channel blockage.

However, cardiac and non-cardiac QT-prolonging drugs often easily target the hERG channel but do not involve in other ion channels to cause arrhythmias. Thus, drugs against COVID-19 with single-ion-channel effects that act on the hERG channel are inevitably potentially arrhythmogenic. Many studies have focused on revealing the biological characteristics of hERG channels to explain possible mechanisms of drug action that involve various drug effects not only on the structure but also on the gating kinetics of these channels.

The hERG channel shares structural homology with other voltage-gated potassium channels (Whicher and MacKinnon, 2016) . The hERG channel is a tetramer, and four hERG subunits are arranged in a ring-shaped manner rather linearly arranged on the membrane (Vandenberg et al., 2012) . Each subunit has six transmembrane fragments (S1-S6), an N-terminal Per-Arnt-Sim (PAS) domain, and a C-terminal cyclic nucleotide-binding domain (cNBD) (Barros et al., 2020; Shi et al., 2020; Warmke and Ganetzky, 1994) . S1-S4 function as a voltage-sensing domain (VSD), and S5-S6 coupled with the intermediate pore loops of the four subunits constitutes the ion permeation pore-gate domain (PD) (Fig 2A) (Barros et al., 2020; Wang et al., 2011) . Recently, a new hERG channel structure obtained from cryo-electron microscopy (cryo-EM), named hERG T , was discovered, with deletions in most of the expected unstructured cytoplasmic regions (Δ141-350 at the N-terminus and Δ871-1005 at the C-terminus) for preventing structural aggregation (Fig 2A) (Wang and MacKinnon, 2017) . hERG T , with a resolution of up to 3.8 Å, retains gating properties similar to those of full-length channels because it does not change the major function of the hERG channel already recognized. hERG T provides new insights into the molecular basis of hERG channel blockade by high-affinity drugs, the binding of hERG channel activators, and unique hERG channel gating kinetics by demonstrating the importance of the special structure of hERG channels for the binding of compounds (Butler et al., 2019; Vandenberg et al., 2017) .

The blockade of the hERG channel by drugs is associated with hERG channel conformational change. In the J o u r n a l P r e -p r o o f early stage of the action potential, the hERG channel slowly opens but rapidly inactivates. As the depolarization voltage continues to decrease, the hERG channel gradually recovers from the inactivation (Witchel et al., 2001) .

Due to recovery from inactivation, hERG currents improve during repolarization followed by a much slower deactivation (Barros et al., 2012; Vandenberg et al., 2017) . The altering rate of inactivation and deactivation reflects the potential potency of drug blockade. Similarly, drugs show different affinities for the channel in its different conformational states (Fig 1C) . More recently, a selectivity filter at the hERG channel was reported as a pharmacological master mechanism to open potassium channels, offering a substantial boost in the design of channel activators to treat aLQTS or diLQTS (Schewe et al., 2019) .

The pharmacology of the hERG channel I Kr is the target of class III antiarrhythmic drugs, such as dofetilide, amiodarone, and D-sotalol. These drugs and non-cardiac drugs, such as those for COVID-19, produce voltage-and dose-dependent hERG channel blockade due to direct blocking of ion pathways once the drugs enter cells (van Noord et al., 2010; Wang and MacKinnon, 2017) . In addition to the direct blocking effect, the disruption of the biogenesis of the hERG channel is also a significant reason for the decrease in the I Kr current (Fig 3) .

Many studies have reported the importance of multiple aromatic residues for drug blockade based on differences in the homology among Kv channels via the mutagenesis of individual residues in the S6 helix (Han et al., 2015; Han et al., 2011; Jie et al., 2017; Rajamani et al., 2006; Sănchez-Chapula et al., 2003; Sánchez-Chapula et al., 2002; Takemasa et al., 2008) . Among them, two aromatic residues of S6, Tyr652 and Phe656, are particularly significant (Fig 2C) . Mutations at these residues can attenuate the drug blocking effect, confirming their high affinity for drug binding. For example, when used in the treatment of COVID-19, CQ-generated channel blockade can be restored by mutation at Tyr652, showing that these key sites participate in channel blockade J o u r n a l P r e -p r o o f (Sánchez-Chapula et al., 2002) . It is believed that the Y652A and F656A mutations decrease the inhibitory effect by 17 times and 75 times, respectively (Helliwell et al., 2018) . In addition to the two key residues above, other residues at the bottom of the pore helix (e.g., Thr623, Ser624, Val625 and Phe557 in the S5 helix) also contribute to drug binding equally as potently as Y652 (Mitcheson et al., 2000; Saxena et al., 2016) .

The structure of hERG T retains all the functions essential for drug binding, which illustrates why these special amino acids of drug binding are so important (Wang and MacKinnon, 2017) . The positions of these amino acids in the sequence and the molecular structure are highlighted, and they are arranged on the surface of elongated, relatively hydrophobic pouches protruding from the central cavity ( Fig 2B) (Wang and MacKinnon, 2017) . These pockets provide potential interaction sites for hERG blockers (Butler et al., 2019). Furthermore, the narrow cavity leads to a more negative electrostatic potential, making it easy for positively charged drugs to bind (Wang and MacKinnon, 2017) . To elucidate the chemical basis of drug binding, higher resolution structures will be needed in combination with molecular dynamics simulations. These simulations could accurately identify where and how drugs bind to the hERG channel and why they bind differently to distinct conformational states of the channel.

As indicated earlier, drugs binding to the pore region of the hERG channel exert a direct blocking effect that disrupts the conduction of ions through the pore. Many different-structured drug groups targeting the hERG As an increasing number of drugs target the hERG channel, more drug studies have confirmed that the above two mechanisms can work together and are probably mediated by different mechanisms (Han et al., 2011; Hancox and Mitcheson, 2006; Rajamani et al., 2006; Takemasa et al., 2008) , making the interfering effect on the hERG channel more complicated.

In general, numerous drugs reduce the generation of the mature form of the hERG channel (155 kDa) by disrupting the forward trafficking of the hERG protein from the endoplasmic reticulum (ER) to the Golgi (Fig 3) .

This process is associated with molecular chaperones that help in protein folding and assembly. For instance, the inhibition of the chaperone protein Hsp90 prevents maturation and promotes the proteasome degradation of hERG protein, thereby reducing the number of mature channels that can be integrated into the cell membrane (Cubeddu, 2016) . Different maturation of the hERG channel protein can be estimated by comparing the expression levels of the two forms of this protein using Western blot. There is currently no definitive, relevant evidence to support the use of drugs that interfere with the maturation of the hERG protein in the treatment of COVID-19. The safe application of these drugs may require detailed information about blocking the intracellular mechanisms of the hERG protein.

Another issue worth considering is that many drugs may alter drug metabolism, which may further increase the plasma levels of drugs that extend the QT interval. Pharmacokinetic interactions usually involve agents metabolized by cytochrome P450 enzymes (van Noord et al., 2010) . P450 (CYP) 3A is the subfamily with the highest expression and includes the isoforms CYP3A4, CYP3A5, CYP3A7, and CYP3A43 (Eichelbaum and Burk, 2001). CYP3A4 is the isoform expressed in the liver and intestine (Eichelbaum and Burk, 2001) , and it can oxidize a variety of drugs through many metabolic processes for detoxification (Dresser et al., 2000) , and CYP3A4 is J o u r n a l P r e -p r o o f responsible for approximately 60% of the metabolism of currently known drugs (Feng et al., 2018; Zhou et al., 2005) . Clinically important CYP3A4 inhibitors include antifungals (e.g., itraconazole and ketoconazole), macrolides (e.g., clarithromycin and erythromycin), antihypertensives (e.g., dihydralazine, verapamil, and diltiazem), and anti-HIV drugs (e.g., ritonavir and delavirdine) (Dresser et al., 2000; Zhou et al., 2005) . These inhibitors can boost the plasma concentration of themselves or other drugs that directly act on the hERG channel and enhance cardiotoxicity (Feng et al., 2018; Zhi et al., 2015) . Among these drugs, ritonavir in lopinavir/ritonavir, which has been shown to be effective for the treatment of COVID-19 as a strong CYP3A4 inhibitor, can increase the oral bioavailability of certain HIV protease inhibitors, such as lopinavir (Dresser et al., 2000) .

combination may prolong the QT interval and therefore increase the incidence of TdP (Saleh et al., 2020 ). An in vitro study also found that CQ and HCQ were effective in controlling SARS-CoV-2 infection (Wang et al., 2020) , and HCQ was more effective than CQ in inhibiting SARS-CoV-2 (Yao et al., 2020) .

There are now more than 100 clinical trials aimed at testing CQ or HCQ in the treatment of COVID-19, and Long-term use of CQ and HCQ has been reported to induce QT prolongation and malignant arrhythmia (Chen et al., 2006; Stas et al., 2008) , and CQ-induced TdP in a COVID-19 patient was also reported (Szekely et al., 2020) .

Antimalarial drugs likely block the hERG channel in heterologous expression models and animal models (Sánchez-Chapula et al., 2001; Traebert et al., 2004) . In feline ventricular cardiomyocytes, CQ blocked several J o u r n a l P r e -p r o o f inward and outward membrane currents, and the order of potency is inwardly rectifying potassium current (I K1 )> I Kr > I Na > I CaL (Sánchez-Chapula et al., 2001) . In contrast, CQ significantly slowed the rate of hERG channel deactivation, reflecting the inability of drug-bound channels to close (Sánchez-Chapula et al., 2002) . 

Azithromycin, as a macrolide antibiotic, is thought to enhance the therapeutic effect of HCQ in COVID-19

patients (Gautret et al., 2020) . Similarly, a combination of azithromycin and CQ/HCQ was shown to be helpful for COVID-19 patients, and there were no reports of death from fatal arrhythmia (Saleh et al., 2020) . However, given the cardiotoxicity of antimalarial drugs themselves, whether azithromycin when combined with them increases adverse reactions and whether we should use these drugs alone or in combination to treat COVID-19 is worth considering. As previously mentioned in a cohort study, the effect of azithromycin combined with CQ/HCQ on prolonging the QT interval is more obvious (Mercuro et al., 2020) , and approximately one-quarter of the QT interval is prolonged excessively (Chorin et al., 2020) . Perhaps azithromycin itself does not usually cause a clinically significant prolongation of the QT interval (Thomsen et al., 2006) , but its use in combination with CQ or HCQ may theoretically increase the risk of TdP (Juurlink, 2020). These conflicting and poor-quality studies suggest that clinicians should carefully weigh the risks and benefits of azithromycin, CQ and HCQ, and it may be advisable to avoid these drugs.

Among macrolides, azithromycin is considered to be the least likely to cause arrhythmia because it is the least cardiotoxic, with an estimated 47 added cardiovascular deaths per million courses according to a report (Ray et al., 2012) . Indeed, studies have confirmed that the rank order of arrhythmogenicity is estimated to be erythromycin> clarithromycin> roxithromycin> azithromycin (Milberg et al., 2002; Ohtani et al., 2000) . Specifically, azithromycin suppresses the I Kr current only at 50 times the clinically related concentration (2075 mg/L), and the inhibition rate is approximately 30% . Unsurprisingly, compared with dofetilide, which has been proven to be an hERG channel blocker, azithromycin has no electrophysiological effects; thus, azithromycin is safe (Avedissian et al., 2019; Thomsen et al., 2006) . However, based on the evidence of macrolides (such as erythromycin) targeting hERG channels (Volberg et al., 2002) , it is necessary to further investigate the interaction of azithromycin with the hERG channel, even though azithromycin mainly increases cardiac Na + current and only slightly blocks I Kr (Yang et al., 2017) . Moreover, azithromycin, as a weaker CYP3A4 inhibitor than homologous antibiotics, may increase the risk of QT prolongation when used in combination with antimalarial drugs in treating COVID-19 patients (Wu et al., 2020) . This seems to explain why azithromycin in combination with CQ or HCQ has a more significant QT prolongation effect.

The HIV protease inhibitor class of antiretroviral drugs has obvious benefits for HIV. As an important CYP3A4 inhibitor, ritonavir can enhance the effect of other protease inhibitors, such as lopinavir and atazanavir (Soliman et al., 2011; Zhou et al., 2005) . The combined preparation of lopinavir/ritonavir has aroused widespread interest after a clinical trial for its use in COVID-19 was conducted (Cao et al., 2020a). The randomized trial found that for severe COVID-19 patients, lopinavir/ritonavir (400 mg and 100 mg, respectively) treatment does not significantly promote clinical improvement, reduce mortality or reduce the detectability of throat RNA of SARS-CoV-2, but it is beneficial for some secondary outcomes (e.g., a shorter time to stay in the intensive care , 2005) . A RCT showed that treatment with ritonavir-enhanced protease inhibitors and non-enhanced regimens had similar effects on QT duration (Soliman et al., 2011) , suggesting that combined treatment regimens may be more beneficial with fewer side effects, and for QT prolongation, the role of ritonavir as an enhancer might not be as important. In particular, 100 mg ritonavir did not cause QT prolongation in healthy subjects (Sarapa et al., 2008) ; therefore, as a CYP3A4 inhibitor, it may generate side effects only when it increases the blood concentration of Various factors can affect the hERG channel to induce QT prolongation, and QT prolongation may also be the result of multiple ion channel actions. In the course of COVID-19, in addition to affecting the lungs, causing interstitial pneumonia and severe acute respiratory distress syndrome (ARDS), SARS-CoV-2 also damages multiple organs due to a massive increase in inflammatory factors, especially in the cardiovascular system, leading to a variety of cardiac problems such as arrhythmia and myocarditis (Guzik et al., 2020; Inciardi et al., 2020; Zheng et al., 2020) . In such cases, the cardiotoxicity of relevant therapeutic drugs may be obscured by the disease itself; therefore, it is necessary to conduct comprehensive clinical management to consider whether to use these drugs, and if necessary, to monitor ECGs. Most drug interactions with the hERG channel induce a prolonged QT interval, which is considered a major risk factor in pharmaceutical drug development, and in addition to the hERG channel, drugs actions on many ion channels causing severe arrhythmias have become a limiting factor for their clinical use (Denning et al., 2016) . Therefore, it may be necessary to determine the cardiotoxicity of a drug before it enters clinical use in the treatment of COVID-19, which requires a sensitive and effective experimental platform to carry out rigorous in vitro experiments as well as tremendous effort for preclinical management.

In 2013, the U.S. FDA proposed an international initiative termed the Comprehensive In Vitro Proarrhythmia Assay (CiPA), which recommends that a multi-electrode array (MEA) be used as a measurement tool, combined with human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), to conduct a preclinical assessment of a drug to evaluate the risk of TdP. The CiPA initiative requires a comprehensive ion current effect, not just I Kr , to evaluate preclinically drug safety, and hiPSC-CMs will become a new chapter in safety assessment At this time, the channel opens again, followed by a slow deactivation process to close the channel. The opening of the channel is necessary for drug binding, and when the channel is closed, the drug is trapped due to the blocking effect and is released when the channel reopens (C).

J o u r n a l P r e -p r o o f

Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats

Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/-and human SCN5A-1795insD+/-iPSC-derived cardiomyocytes

Drug-induced long QT syndrome: hERG K + channel block and disruption of protein trafficking by fluoxetine and norfluoxetine

Azithromycin and the risk of cardiovascular death

Long QT syndrome modelling with cardiomyocytes derived from human-induced pluripotent stem cells

A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells

The Effect of Chloroquine

Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain

Molecular determinants of voltage-dependent human ether-a-go-go related gene

Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes

Guidance On Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society

Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies

New potential binding determinant for hERG channel inhibitors

A pharmacological master key mechanism that unlocks the selectivity filter gate in K channels

Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes

Modulation of hERG K + channel deactivation by voltage sensor relaxation. Frontiers in pharmacology 11

Molecular pathogenesis of long QT syndrome type 2

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine

Lopinavir-ritonavir in severe COVID-19

Chloroquine-induced torsade de pointes in a COVID-19 patient

Coexistence of hERG current block and disruption of protein trafficking in ketoconazole

No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block

Inhibition of hERG K + currents by antimalarial drugs in stably transfected HEK293 cells

Towards a structural view of drug binding to hERG K + channels

hERG K + channels: structure, function, and clinical significance

Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem?

Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study

Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics

Mapping the sequence of conformational changes underlying selectivity filter gating in the KV11

Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Cryo-EM structure of the open human ether-à-go-go-related

A family of potassium channel genes related to eag in Drosophila and mammals

Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation

Azithromycin Causes a Novel Proarrhythmic Syndrome

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

COVID-19 and the cardiovascular system

The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs